U. Fuhr

发表

What is the true risk of a pharmacokinetic drug–drug interaction?

U. Fuhr, 2007, European Journal of Clinical Pharmacology.

Improvement in the handling of drug–drug interactions

U. Fuhr, 2008, European Journal of Clinical Pharmacology.

Molecular-epidemiological aspects of carcinogenesis : the role of xenobiotic metabolizing enzymes *

V. Diehl, H. Tesch, U. Fuhr, 2002 .

Site-specific absence of microfibrillar-associated protein 4 (MFAP4) from the internal elastic membrane of arterioles in the rheumatoid arthritis synovial membrane an immunohistochemical study in patients with advanced rheumatoid arthritis versus osteoarthritis

Resta, I. Brandslund, D. Gurwitz, 2019 .

Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey.

I. Brandslund, D. Gurwitz, J. Lunshof, 2019, Pharmacogenomics.

Impact of Impaired Renal Function on the Pharmacokinetics of the Antiepileptic Drug Lacosamide

U. Fuhr, W. Cawello, U. Hering, 2013, Clinical Pharmacokinetics.

CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.

U. Fuhr, A. Gaedigk, J. Leeder, 2010, Pharmacogenomics.

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients

Thomas Zander, Martin Kocher, Sebastian Frechen, 2015, The AAPS Journal.

Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

U. Fuhr, F. Sörgel, A. Jetter, 2005, Antimicrobial Agents and Chemotherapy.

Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups

U. Fuhr, T. Lehr, M. Schwab, 2022, CPT: pharmacometrics & systems pharmacology.

Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.

U. Fuhr, J. Buters, A. Labedzki, 2002, Biochemical pharmacology.

Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?

Jürgen Brockmöller, Uwe Fuhr, U. Fuhr, 2005, Nature Reviews Drug Discovery.

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

U. Fuhr, U. Jaehde, D. Frank, 2007, European Journal of Clinical Pharmacology.

A Population Pharmacokinetic Model of (R)‐ and (S‐) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers

U. Fuhr, R. Stein, P. Rubenwolf, 2020, Journal of clinical pharmacology.

Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model

U. Fuhr, J. Stingl, Weidong Wu, 2013, Clinical Pharmacokinetics.

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol

U. Fuhr, M. Bilal, M. Taubert, 2021, Clinical Pharmacokinetics.

Natriuretic peptides in therapy for decompensated heart failure

U. Fuhr, E. Caglayan, F. Er, 2011, European Journal of Clinical Pharmacology.

Drug Cocktail Interaction Study on the Effect of the Orally Administered Lavender Oil Preparation Silexan on Cytochrome P450 Enzymes in Healthy Volunteers

U. Fuhr, A. Dienel, S. Schläfke, 2013, Drug Metabolism and Disposition.

Pharmacokinetics of inhaled anaesthetics in a clinical setting: description of a novel method based on routine monitoring data.

U. Fuhr, S. Rietbrock, H. Wissing, 2000, British journal of anaesthesia.

Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.

U. Fuhr, M. Fassnacht, S. Hamacher, 2018, European journal of endocrinology.

Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P‐Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?

U. Fuhr, M. Kinzig, F. Sörgel, 2018, Clinical pharmacology and therapeutics.

Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients

U. Fuhr, K. Scharffetter-Kochanek, I. Tantcheva-Poór, 2001, The British journal of dermatology.

Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors

U. Fuhr, J. Gojo, S. Poschner, 2022, Cancer Chemotherapy and Pharmacology.

Phenotyping Studies to Assess the Effects of Phytopharmaceuticals on In Vivo Activity of Main Human Cytochrome P450 Enzymes

U. Fuhr, G. Zadoyan, 2012, Planta Medica.

A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.

U. Fuhr, M. Kinzig, F. Sörgel, 2020, Journal of clinical pharmacology.

Lacking effect of grapefruit juice on theophylline pharmacokinetics.

U. Fuhr, A. Staib, V. Steinijans, 1995, International journal of clinical pharmacology and therapeutics.

Effects of grapefruit juice on the pharmacokinetics of sildenafil

U. Fuhr, F. Sörgel, A. Jetter, 2002, Clinical pharmacology and therapeutics.

Effects of grapefruit juice and smoking on verapamil concentrations in steady state

U. Fuhr, S. Harder, P. López-Rojas, 2002, European Journal of Clinical Pharmacology.

The effect of silymarin on oral nifedipine pharmacokinetics.

U. Fuhr, A. Jetter, U. Mengs, 2007, Planta medica.

The fate of naringin in humans: A key to grapefruit juice‐drug interactions?

U. Fuhr, A. L. Kummert, Anja L. Kummert, 1995, Clinical pharmacology and therapeutics.

Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants.

U. Fuhr, D. Rokitta, 2010, Current drug metabolism.

Low risk pragmatic trials do not always require participants’ informed consent

U. Fuhr, F. Rosendaal, S. Treweek, 2019, BMJ.

Absorption of ipsapirone along the human gastrointestinal tract.

U. Fuhr, A. Staib, D. Liermann, 1994, British journal of clinical pharmacology.

Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

U. Fuhr, M. Kinzig, F. Sörgel, 2009, European Journal of Clinical Pharmacology.

Plasma 4β‐Hydroxycholesterol: An Endogenous CYP3A Metric?

U. Fuhr, A. Jetter, D. Lütjohann, 2009, Clinical pharmacology and therapeutics.

Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam

U. Fuhr, A. Suleiman, S. Frechen, 2014, Journal of clinical pharmacology.

Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers

R. Hoerr, U. Fuhr, A. Dienel, 2011, European Journal of Clinical Pharmacology.

Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P‐glycoprotein in HIV‐infected Patients

U. Fuhr, A. Jetter, C. Lehmann, 2008, Clinical pharmacology and therapeutics.

Frequency and Types of Pathological Upper Gastrointestinal Endoscopy Findings in Clinically Healthy Individuals

U. Fuhr, A. König, C. Benz, 2020, Drugs in R&D.

Year : 2009 In vivo role of cytochrome P 450 2 E 1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans

U. Fuhr, M. Kinzig, F. Sörgel, 2009 .

Influence of posture on pharmacokinetics

U. Fuhr, Christian Queckenberg, 2009, European Journal of Clinical Pharmacology.

Absorption, Pharmacokinetics, and Safety of Triclosan after Dermal Administration

Uwe Fuhr, J. Meins, U. Fuhr, 2009, Antimicrobial Agents and Chemotherapy.

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

U. Fuhr, A. Jetter, G. Fätkenheuer, 2008, European Journal of Clinical Pharmacology.

Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine

U. Fuhr, E. Erdmann, F. Er, 2010, European Journal of Clinical Pharmacology.

Dosing accuracy of commonly used disposable insulin pens

U. Fuhr, M. Schubert-Zsilavecz, M. Abdel-Tawab, 2010, Current medical research and opinion.

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

U. Fuhr, N. Semmo, F. Er, 2011, European Journal of Clinical Pharmacology.

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide

U. Fuhr, J. Brockmöller, F. Sörgel, 2004, European Journal of Clinical Pharmacology.

Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin

U. Fuhr, M. Schwab, E. Schaeffeler, 2020, Scientific Reports.

Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies.

U. Fuhr, M. Kinzig, F. Sörgel, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A Clinical Drug‐Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin

U. Fuhr, M. Kinzig, F. Sörgel, 2019, Clinical pharmacology and therapeutics.

Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients

U. Fuhr, M. Hallek, U. Jaehde, 2021, BMC cancer.

Plasma and Tissue Pharmacokinetics of Epirubicin and Paclitaxel in Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Primary Breast Cancer

U. Fuhr, M. Untch, U. Jaehde, 2007, Clinical pharmacology and therapeutics.

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

J. Franklin, U. Fuhr, J. Wolf, 2020, Cancer medicine.

A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers

U. Fuhr, X. Tian, Xiaojian Zhang, 2019, Front. Pharmacol..

Clinical impact of fluvoxamine-mediated long QTU syndrome

U. Fuhr, F. Er, A. Nia, 2011, European Journal of Clinical Pharmacology.

Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin

U. Fuhr, O. Doroshyenko, 2009, Clinical pharmacokinetics.

Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples

U. Holzgrabe, U. Fuhr, M. Kinzig, 2017, Pharmacology.

Response to “Impact of Acute Alcohol Exposure on P‐Glycoprotein Function at the Blood–Brain Barrier Assessed Using 11C‐Metoclopramide PET Imaging”

U. Fuhr, Christina Trueck, Chih‐hsuan Hsin, 2018, Clinical pharmacology and therapeutics.

Pharmacokinetic Phenotyping to Predict Drug–Drug Interactions: Time to Divorce the Hybrid Concept of Simultaneous Mechanistic‐Based and Exposure‐Based Assessment

U. Fuhr, 2018, Clinical pharmacology and therapeutics.

The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro

U. Fuhr, D. Rokitta, Kay Pfeiffer, 2013, Toxicology mechanisms and methods.

Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual

U. Fuhr, A. Gaedigk, D. Frank, 2008, European Journal of Clinical Pharmacology.

Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes.

U. Fuhr, A. Staib, T. Wolff, 1990, Drug metabolism and disposition: the biological fate of chemicals.

DMD050203 987..993

U. Fuhr, A. Dienel, S. Schläfke, 2013 .

Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

U. Fuhr, A. Jetter, E. Schömig, 2010, Antiviral therapy.

Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.

U. Fuhr, M. Zaigler, I. Tantcheva‐poór, 2000, International journal of clinical pharmacology and therapeutics.

Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.

U. Fuhr, K. Rost, 1994, Pharmacogenetics.

Assessment of CYP1A2 activity in clinical practice: why, how, and when?

U. Fuhr, A. Jetter, Mirko S Faber, 2005, Basic & clinical pharmacology & toxicology.

University of Birmingham Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency

U. Fuhr, W. Arlt, D. Maiter, 2010 .

Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited.

U. Fuhr, F. Sörgel, Wafaâ Jabrane, 2019, Annual review of pharmacology and toxicology.

The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers

U. Fuhr, F. Sörgel, A. Jetter, 2005, Clinical pharmacology and therapeutics.

EFFECT OF PROPIVERINE ON CYTOCHROME P450 ENZYMES: A COCKTAIL INTERACTION STUDY IN HEALTHY VOLUNTEERS

U. Fuhr, F. Sörgel, A. Jetter, 2005, Drug Metabolism and Disposition.

Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity

U. Fuhr, U. Jaehde, A. Jetter, 2008, European Journal of Clinical Pharmacology.

Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule).

U. Fuhr, A. Staib, D. Liermann, 1989, The American journal of medicine.

Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps.

U. Fuhr, G. Eisenbrand, E. Richling, 2012, Molecular nutrition & food research.

Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops

U. Fuhr, K. Abduljalil, O. Doroshyenko, 2008, European Journal of Clinical Pharmacology.

Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol

U. Fuhr, F. Mayer, U. Jaehde, 2021, Cancers.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

U. Fuhr, A. Lazar, J. Kirchheiner, 2008, Clinical pharmacokinetics.

Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers

U. Fuhr, M. Kinzig, F. Sörgel, 2010, Clinical pharmacology and therapeutics.

Do data presented at an American Society for Clinical Pharmacology and Therapeutics meeting make it to full publication?

U. Fuhr, M. Riessland, D. Tomalik-Scharte, 2004, Clinical pharmacology and therapy.

Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler.

U. Fuhr, A. Suleiman, S. Frechen, 2015, Drug metabolism and pharmacokinetics.

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler

U. Fuhr, M. Abdel-Tawab, B. Wachall, 2013, European Journal of Clinical Pharmacology.

A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects

U. Fuhr, M. Taubert, M. Bilal, 2022, Naunyn-Schmiedeberg's archives of pharmacology.

Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients

U. Fuhr, L. Holdt, M. Vogeser, 2016, Antimicrobial Agents and Chemotherapy.

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

U. Fuhr, S. Loibl, N. Harbeck, 2014, Breast Care.

Development of a new G-CSF product based on biosimilarity assessment.

U. Fuhr, P. Gascón, A. Makhson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic–pharmacodynamic model in gastrointestinal cancer patients

U. Fuhr, M. Karlsson, U. Jaehde, 2020, Cancer Chemotherapy and Pharmacology.

Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose

U. Fuhr, M. Vogeser, J. Zander, 2018, The Journal of antimicrobial chemotherapy.

Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

U. Fuhr, J. Brockmöller, C. Rodríguez-Antona, 2008, Pharmacogenomics.

A population pharmacokinetic model for creatinine with and without ingestion of a cooked meat meal

U. Fuhr, Zhendong Chen, M. Mayersohn, 2022, European Journal of Clinical Pharmacology.

Affinities of dihydrocodeine and its metabolites to opioid receptors.

U. Fuhr, U. Gundert-Remy, G. Skopp, 2002, Pharmacology & toxicology.

Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.

U. Fuhr, K. Beckurts, S. Rietbrock, 2000, Pharmacology & toxicology.

CSF pharmacokinetics of ceftazidime in neurosurgical patients with an external ventriculostomy

U. Fuhr, A. Staib, S. Harder, 2005, Infection.

Effects of Temafloxacin and Ciprofloxacin on the Pharmacokinetics of Caffeine

U. Fuhr, G. Granneman, M. Kinzig, 1992, Clinical pharmacokinetics.

Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide

M. Hellmich, U. Fuhr, J. Stingl, 2011, Drug Metabolism and Disposition.

The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.

U. Fuhr, A. Jetter, U. Zanger, 2009, Basic & clinical pharmacology & toxicology.

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

U. Fuhr, U. Klotz, J. Brockmöller, 2008, European Journal of Clinical Pharmacology.

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

U. Fuhr, M. Hallek, K. Kreuzer, 2012, European Journal of Clinical Pharmacology.

Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry.

U. Fuhr, A. Jetter, W. Gebhardt, 2004, Rapid communications in mass spectrometry : RCM.

Rate-limiting biotransformation of triamterene is mediated by CYP1A2.

U. Fuhr, M. Zaigler, H. Spahn‐Langguth, 2005, International journal of clinical pharmacology and therapeutics.

The role of active metabolites in dihydrocodeine effects.

U. Fuhr, U. Gundert-Remy, G. Skopp, 2003, International journal of clinical pharmacology and therapeutics.

Cytochrome P450 enzymes contributing to demethylation of maprotiline in man.

U. Fuhr, A. Hölscher, K. Beckurts, 2002, Pharmacology & toxicology.

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler

U. Fuhr, M. Abdel-Tawab, B. Wachall, 2013, European Journal of Clinical Pharmacology.

The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine

J. Borlak, U. Munzel, U. Fuhr, 2006, The Pharmacogenomics Journal.

Channeling the flood of meta-analyses

M. Hellmich, U. Fuhr, 2015, European Journal of Clinical Pharmacology.

Omeprazole weakly inhibits CYP1A2 activity in man.

U. Fuhr, J. Brockmöller, I. Roots, 1999, International journal of clinical pharmacology and therapeutics.

Mesalazine pharmacokinetics and NAT2 phenotype

U. Fuhr, M. Kinzig, F. Sörgel, 2008, European Journal of Clinical Pharmacology.

Dermal absorption of permethrin following topical administration

J. Meins, U. Fuhr, A. Jetter, 2005, European Journal of Clinical Pharmacology.

Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane.

U. Fuhr, S. Rietbrock, H. Wissing, 2000, British journal of anaesthesia.

Pharmacogenetics of Oral Anticoagulants

U. Fuhr, A. Lazar, J. Kirchheiner, 2008, Clinical pharmacokinetics.

Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.

U. Fuhr, R. Stein, P. Rubenwolf, 2013, The Journal of urology.

Determination of free and total 7-hydroxycoumarin in urine and serum by capillary electrophoresis.

U. Fuhr, M. Smyth, B. Deasy, 1995, Journal of chromatography. B, Biomedical applications.

Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes.

U. Fuhr, K. Beckurts, S. Rietbrock, 1999, Pharmacology & toxicology.

Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation

U. Fuhr, M. Hallek, K. Abduljalil, 2009, Antimicrobial Agents and Chemotherapy.

Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2

U. Fuhr, F. Sörgel, M. Zaigler, 1999, Clinical pharmacology and therapeutics.

Absence of Effect of Rufloxacin on Theophylline Pharmacokinetics in Steady State

U. Fuhr, A. Staib, F. Sörgel, 1998, Antimicrobial Agents and Chemotherapy.

Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations.

U. Fuhr, A. Staib, T. Wolff, 1989, The American journal of medicine.

A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions

P. Neuvonen, U. Fuhr, T. Lehr, 2019, Clinical Pharmacokinetics.

Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.

U. Fuhr, A. Staib, S. Harder, 1990, British journal of clinical pharmacology.

The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitro

U. Fuhr, F. Sörgel, R. Höhl, 2020, European Journal of Clinical Pharmacology.

Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure

U. Fuhr, F. Sörgel, Gillian Smith, 2004, European Journal of Clinical Pharmacology.

Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects

U. Holzgrabe, U. Fuhr, M. Kinzig, 2018, Pharmacology.

Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.

U. Fuhr, A. Staib, K. Klittich, 1993, British journal of clinical pharmacology.

Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition.

U. Fuhr, S. Frechen, Dominik Dahlinger, 2016, Journal of pharmacological and toxicological methods.

Clinical Pharmacokinetics of Trospium Chloride

U. Fuhr, A. Jetter, O. Doroshyenko, 2005, Clinical pharmacokinetics.

Induction of Drug Metabolising Enzymes

Uwe Fuhr, U. Fuhr, 2000, Clinical pharmacokinetics.

Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections

U. Fuhr, A. Vente, A. Dalhoff, 2018, Antimicrobial Agents and Chemotherapy.

Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach

U. Fuhr, A. Jetter, J. Kirchheiner, 2007, Clinical pharmacology and therapeutics.

Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.

P. Beaune, D. Grant, U. Fuhr, 1996, Pharmacogenetics.

Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms.

U. Fuhr, A. Staib, J. Doehmer, 1992, Biochemical pharmacology.

Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro

U. Fuhr, A. Staib, F. Sörgel, 1992, Antimicrobial Agents and Chemotherapy.

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

U. Fuhr, J. Wolf, U. Jaehde, 2011, Clinical pharmacokinetics.

Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.

U. Fuhr, K. Beckurts, M. Zaigler, 2001, International journal of clinical pharmacology and therapeutics.

Systematic screening for pharmacokinetic interactions during drug development.

B G Woodcock, H K Kroemer, U. Fuhr, 1996, International journal of clinical pharmacology and therapeutics.

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Uwe Fuhr, Jürgen Wolf, U. Fuhr, 2011, Clinical pharmacokinetics.

Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.

U. Fuhr, U. Jaehde, K. Mross, 2012, Journal of pharmaceutical and biomedical analysis.

A Novel Toxicokinetic Modeling of Cypermethrin and Permethrin and Their Metabolites in Humans for Dose Reconstruction from Biomarker Data

U. Fuhr, M. Bouchard, J. Côté, 2014, PloS one.

A Model‐Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients

U. Fuhr, U. Jaehde, J. Zander, 2021, Clinical pharmacology and therapeutics.

Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.

U. Fuhr, A. Jetter, 2002, Die Pharmazie.

Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens

U. Fuhr, M. Vogeser, J. Zander, 2017, The Journal of antimicrobial chemotherapy.

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer

U. Fuhr, F. Dietlein, B. Neumaier, 2015, Oncotarget.

Modeling NSCLC Progression: Recent Advances and Opportunities Available

U. Fuhr, L. Nogova, A. Suleiman, 2013, The AAPS Journal.

A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.

U. Fuhr, M. Kinzig, F. Sörgel, 2019, Journal of pharmaceutical and biomedical analysis.

Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine

U. Fuhr, A. Staib, E. Brendel, 1996, European Journal of Clinical Pharmacology.

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

J Kirchheiner, U. Fuhr, A. Lazar, 2008, The Pharmacogenomics Journal.

Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function

E. Schaeffner, U. Fuhr, P. Martus, 2021, Scientific Reports.

Detection of a novel 1905C-->T mutation within the dihydropyrimidine dehydrogenase gene and potential for misclassification with the exon 14-skipping mutation.

U. Fuhr, H. Pfister, D. Gründemann, 2003, Clinical chemistry.

Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan

U. Fuhr, U. Jaehde, A. Jetter, 2010, Clinical pharmacology and therapeutics.

Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study

Iva S. Kostadinova, M. Memo, R. Huupponen, 2018, Clinical pharmacology and therapeutics.

Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling.

W. Huisinga, U. Fuhr, C. Kloft, 2021, European journal of endocrinology.

Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients

U. Fuhr, M. Hallek, U. Jaehde, 2021, BMC Cancer.

Toxicokinetics of Acrylamide in Humans after Ingestion of a Defined Dose in a Test Meal to Improve Risk Assessment for Acrylamide Carcinogenicity

U. Fuhr, J. Angerer, F. Sörgel, 2006, Cancer Epidemiology Biomarkers & Prevention.

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking

U. Fuhr, Mirko S Faber, 2004, Clinical pharmacology and therapeutics.

Drug metabolism biosensors: electrochemical reactivities of cytochrome P450cam immobilised in synthetic vesicular systems.

Z Zhang, P. Ortiz de Montellano, U. Fuhr, 1998, Journal of pharmaceutical and biomedical analysis.

Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.

U. Fuhr, M. Zaigler, S. Rietbrock, 1999, Pharmacogenetics.

Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education

G. Siest, J. Licinio, D. Gurwitz, 2005, The Pharmacogenomics Journal.

Assessment of urinary mephenytoin metrics to phenotype for CYP 2 C 19 and CYP 2 B 6 activity

U. Fuhr, U. Jaehde, A. Jetter, 2008 .

Chapter 13 - Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters

U. Fuhr, A. Lazar, D. Tomalik‐Scharte, 2004 .

Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin.

U. Fuhr, P. Saenger, D. Tuculanu, 2010, European journal of endocrinology.

In vivo Role of Cytochrome P450 2E1 and Glutathione-S-Transferase Activity for Acrylamide Toxicokinetics in Humans

U. Fuhr, M. Kinzig, F. Sörgel, 2009, Cancer Epidemiology Biomarkers & Prevention.

Natriuretic peptides in therapy for decompensated heart failure

U. Fuhr, E. Caglayan, F. Er, 2012, European Journal of Clinical Pharmacology.

Study on the dosing accuracy of commonly used disposable insulin pens.

Manfred Schubert-Zsilavecz, Uwe Fuhr, U. Fuhr, 2012, Diabetes technology & therapeutics.

Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers

U. Fuhr, Joseph Chiesa, A. Dalhoff, 2017, Antimicrobial Agents and Chemotherapy.

The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro

U. Fuhr, D. Rokitta, D. Tomalik‐Scharte, 2013, Toxicology mechanisms and methods.

Grapefruit juice increases oral nimodipine bioavailability.

U. Fuhr, A. Staib, M. Zaigler, 1998, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers.

U. Fuhr, Christian Queckenberg, P. Di Gion, 2011, Clinical therapeutics.

Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women.

U. Fuhr, A. Staib, M. Zaigler, 2000, International journal of clinical pharmacology and therapeutics.

Uroporphyrinogen oxidation catalyzed by human cytochromes P450.

U. Fuhr, P. Sinclair, N. Gorman, 1998, Drug metabolism and disposition: the biological fate of chemicals.

How may Anticancer Chemotherapy with Fluorouracil be Individualised?

U. Fuhr, A. Jetter, Su-arpa Ploylearmsaeng, 2006, Clinical pharmacokinetics.

Reactivities of Organic Phase Biosensors 3: Electrochemical Study of Cytochrome P450cam Immobilized in a Methyltriethoxysilane Sol‐Gel

Emmanuel I. Iwuoha, Uwe Fuhr, Malcolm R. Smyth, 2000 .

Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis

U. Fuhr, M. Zeitlinger, M. Taubert, 2023, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Effect of pretreatment with the selective β1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and β-adrenoceptor subtype specific occupancy of celiprolol in healthy man

U. Fuhr, G. Belz, C. Mey, 2004, European Journal of Clinical Pharmacology.

Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration.

U. Fuhr, A. Jetter, M. Zaigler, 2004, International journal of clinical pharmacology and therapeutics.

Population Pharmacokinetics as a Tool to Reevaluate the Complex Disposition of Ethanol in the Fed and Fasted States

U. Fuhr, U. Klotz, M. Schwab, 2023, Journal of clinical pharmacology.

Clinical impact of fluvoxamine-mediated long QTU syndrome

U. Fuhr, F. Er, A. Nia, 2011, European Journal of Clinical Pharmacology.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years

A. Boddy, U. Fuhr, J. Schellens, 2013, Cancer Chemotherapy and Pharmacology.

Drug Interactions with Grapefruit Juice

U. Fuhr, 1998, Drug safety.

A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure

U. Fuhr, M. Zeitlinger, P. Matzneller, 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples

U. Holzgrabe, U. Fuhr, M. Kinzig, 2016, Pharmacology.

A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole

P. Neuvonen, U. Fuhr, K. Olkkola, 2013, Clinical Pharmacokinetics.

An amperometric biosensor with human CYP3A4 as a novel drug screening tool.

James F Rusling, Uwe Fuhr, U. Fuhr, 2003, Biochemical pharmacology.

Study of coumarin metabolism by human liver microsomes using capillary electrophoresis

U. Fuhr, M. Smyth, B. Deasy, 1995 .

Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2.

F. Sanz, U. Fuhr, F. Sörgel, 1993, Molecular pharmacology.

Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations

U. Fuhr, M. Wargenau, V. Kubeš, 2015, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin’s Lymphoma and its Effect on Myelotoxicity

V. Diehl, U. Fuhr, U. Jaehde, 2007, Clinical pharmacokinetics.

The role of human CYP 2 C 8 and CYP 2 C 9 variants in pioglitazone metabolism in vitro

U. Fuhr, A. Jetter, U. Zanger, 2009 .

Exposure to acrolein exceeds that to acrylamide: Monitoring mercapturic acids in human urine after c

U. Fuhr, G. Eisenbrand, E. Richling, 2011 .

Abstract 4692: Comparison of dietary exposure to acrylamide and acrolein: monitoring mercapturic acids in human urine after consumption of potato crisps

U. Fuhr, G. Eisenbrand, E. Richling, 2010 .

Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents.

U. Fuhr, J. Kirchheiner, 2005, International journal of clinical pharmacology and therapeutics.

Using a three-compartment model improves the estimation of iohexol clearance to assess glomerular filtration rate

E. Schaeffner, U. Fuhr, P. Martus, 2018, Scientific Reports.

Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers

R. Hoerr, U. Fuhr, A. Dienel, 2011, European Journal of Clinical Pharmacology.

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

U. Fuhr, J. Brockmöller, A. Jetter, 2006, Clinical pharmacology and therapeutics.

Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration

U. Fuhr, M. Kinzig, F. Sörgel, 2009, Antimicrobial Agents and Chemotherapy.

Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients

U. Fuhr, U. Jaehde, M. Taubert, 2023, Antimicrobial agents and chemotherapy.

Running title : Effect of propiverine on cytochrome P 450 enzymes : a cocktail interaction study in healthy volunteers

U. Fuhr, F. Sörgel, A. Jetter, 2005 .

Theophylline metabolism affected by mexiletine

U. Fuhr, A. Staib, I. Roots, 1992, Clinical pharmacology and therapeutics.

Modeling Tumor Dynamics and Overall Survival in Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib

T. Zander, U. Fuhr, J. Wolf, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Modeling NSCLC Progression: Recent Advances and Opportunities Available

U. Fuhr, L. Nogova, A. Suleiman, 2013, The AAPS Journal.

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients

T. Zander, U. Fuhr, J. Wolf, 2015, The AAPS Journal.

Physiologically Based Pharmacokinetic Modeling of Bergamottin and 6,7‐Dihydroxybergamottin to Describe CYP3A4 Mediated Grapefruit‐Drug Interactions

U. Fuhr, T. Lehr, D. Selzer, 2023, Clinical pharmacology and therapeutics.

["Clinically significant" new drug interactions].

U. Fuhr, 2000, Medizinische Klinik.

Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis

U. Fuhr, M. Kinzig, F. Sörgel, 2020, The Journal of antimicrobial chemotherapy.

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

U. Fuhr, M. Hallek, K. Kreuzer, 2012, European Journal of Clinical Pharmacology.

GENES BY POPULATION PHARMACOKINETICS OF DEXTROMETHORPHAN

U. Fuhr, U. Jaehde, A. Jetter, 2017 .

Assessment of activity levels for CYP 2 D 6 * 1 , CYP 2 D 6 * 2 , and CYP 2 D 6 * 41 genes by population pharmacokinetics of dextromethorphan

U. Fuhr, U. Jaehde, A. Jetter, 2016 .

Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Vancomycin in Patients with External Ventricular Drain

U. Fuhr, C. Dorn, K. Dimitriadis, 2023, Antimicrobial agents and chemotherapy.

Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis

U. Fuhr, M. Kinzig, F. Sörgel, 2020, medRxiv.

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

U. Fuhr, M. Hallek, K. Kreuzer, 2012 .

Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics

U. Fuhr, M. Zeitlinger, R. Helbok, 2020, Neurocritical Care.

In vitro validation of an in vivo phenotyping drug cocktail for major drug transporters in humans.

U. Fuhr, G. Jedlitschky, Y. Hagos, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2

U. Fuhr, M. Siewert, B. Woodcock, 1992, European Journal of Clinical Pharmacology.

Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation.

W. Lehmacher, U. Fuhr, F. Sörgel, 2005, International journal of clinical pharmacology and therapeutics.

The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study.

U. Fuhr, N. Harbeck, J. Wolf, 2011, Journal of Clinical Oncology.

The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro

U. Fuhr, D. Rokitta, D. Tomalik‐Scharte, 2013, Toxicology Mechanisms and Methods.

Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

U. Fuhr, J. Brockmöller, I. Meineke, 2008, Pharmacogenomics.